SCHEMBL25814907

SCHEMBL25814907

Cc1c(C)n(C)c2ccc(C(=O)N(C)CCN3CCCCC3C)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 3/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 7/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 2/20 0.43
TP53 P04637 2/20 0.42
RAD52 P43351 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
RAB9A P51151 1/20 0.39
SCN1A P35498 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN3A Q9NY46 1/20 0.39
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25812105 0.89 KDM4E (0.43) KDM4EHSD17B10TSHRNPSR1MAPT
SCHEMBL25811310 0.81 RAD52 (0.59) KDM4EHSD17B10MAPTALDH1A1MAPK1
SCHEMBL25813149 0.79 RAD52 (0.62) KDM4EHSD17B10MAPTALDH1A1MAPK1
SCHEMBL25811891 0.77 MAPT (0.47) KDM4EHSD17B10TSHRNPSR1MAPT
SCHEMBL25813002 0.75 MAPT (0.56) KDM4EHSD17B10MAPTALDH1A1MAPK1
SCHEMBL25813578 0.74 MAPT (0.49) KDM4EHSD17B10MAPTALDH1A1MAPK1
SCHEMBL2161458 0.67 KMT2A (0.62) KDM4EMAPTALDH1A1MAPK1TP53
SCHEMBL2161575 0.67 HTR3A (0.65) MAPTTP53MEN1KMT2A
SCHEMBL2161450 0.66 KMT2A (0.68) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL25811801 0.66 KMT2A (0.61) KDM4EHSD17B10MAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KDM4E 1465/4885HSD17B10 1893/4885TSHR 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.